MktsMarkets

Eledon Pharmaceuticals, Inc.
NASDAQ: ELDNKey statistics
ELDN News
Stories mentioning ELDN from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 17,197 | 17,491 | 14,969 | 20,276 | 13,531 | 17,928 | 16,520 | 10,106 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 21,181 | 21,484 | 19,070 | 24,733 | 17,964 | 24,696 | 20,510 | 14,502 |
| Operating Income (Loss) | (21,181) | (19,070) | (24,733) | (17,964) | (20,510) | (14,502) | ||
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 1,118 | 540.00 | 1,047 | 1,224 | 1,409 | 1,439 | 1,042 | 869.00 |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (39,025) | (10,447) | (17,459) | (11,216) | (6,495) | (44,617) | 76,971 | (44,907) |
| Earnings Per Share (Basic) | (0.33) | (0.13) | (0.21) | (0.13) | (0.08) | (0.92) | 1.05 | (0.92) |
| Earnings Per Share (Diluted) | (0.33) | (0.13) | (0.21) | (0.13) | (0.08) | (0.92) | (0.28) | (0.92) |
| Weighted Average Shares Outstanding (Basic) | 112,424 | 81,836 | 77,156 | 77,156 | 77,127 | 48,544 | 51,946 | 42,278 |
| Weighted Average Shares Outstanding (Diluted) | 112,424 | 81,836 | 77,156 | 77,156 | 77,127 | 48,544 | 55,478 | 42,278 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About ELDN
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) is a stock listed on the Nasdaq Stock Market under the ticker symbol ELDN. It last traded at $2.30 (Oct 22, 2026, 4:00 PM ET), up 1.8% on the day. That gives Eledon Pharmaceuticals a market capitalisation of $186.9M.
Over the past 52 weeks ELDN has traded between $1.35 and $4.60.
For the quarter ended Mar 31, 2026 it reported a net loss of $39.0M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$39.0M |
| Dec 31, 2025 | — | -$10.4M |
| Sep 30, 2025 | — | -$17.5M |
| Jun 30, 2025 | — | -$11.2M |
From Eledon Pharmaceuticals’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…